Legal & General Group Plc Acquires 45,825 Shares of Integra LifeSciences Holdings Corporation $IART

Legal & General Group Plc grew its holdings in Integra LifeSciences Holdings Corporation (NASDAQ:IART) by 21.3% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 261,242 shares of the life sciences company’s stock after acquiring an additional 45,825 shares during the period. Legal & General Group Plc owned about 0.34% of Integra LifeSciences worth $3,205,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently made changes to their positions in IART. Caitong International Asset Management Co. Ltd lifted its holdings in Integra LifeSciences by 205.9% in the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 3,132 shares of the life sciences company’s stock worth $38,000 after purchasing an additional 2,108 shares in the last quarter. AlphaQuest LLC bought a new stake in shares of Integra LifeSciences during the second quarter valued at approximately $73,000. EMC Capital Management purchased a new position in shares of Integra LifeSciences in the second quarter worth $75,000. CWM LLC boosted its position in shares of Integra LifeSciences by 32.6% during the second quarter. CWM LLC now owns 8,834 shares of the life sciences company’s stock worth $108,000 after acquiring an additional 2,170 shares during the last quarter. Finally, MassMutual Private Wealth & Trust FSB grew its stake in Integra LifeSciences by 6,017.6% during the second quarter. MassMutual Private Wealth & Trust FSB now owns 10,094 shares of the life sciences company’s stock valued at $124,000 after acquiring an additional 9,929 shares in the last quarter. Hedge funds and other institutional investors own 84.78% of the company’s stock.

Integra LifeSciences Stock Performance

NASDAQ IART opened at $13.24 on Friday. The business’s 50 day moving average price is $13.42 and its 200-day moving average price is $13.38. Integra LifeSciences Holdings Corporation has a fifty-two week low of $10.87 and a fifty-two week high of $27.13. The company has a market cap of $1.03 billion, a P/E ratio of -2.05 and a beta of 1.06. The company has a debt-to-equity ratio of 1.73, a quick ratio of 1.80 and a current ratio of 3.14.

Integra LifeSciences (NASDAQ:IART) last posted its quarterly earnings data on Thursday, October 30th. The life sciences company reported $0.54 EPS for the quarter, topping the consensus estimate of $0.43 by $0.11. Integra LifeSciences had a negative net margin of 30.15% and a positive return on equity of 14.06%. The company had revenue of $402.06 million during the quarter, compared to analyst estimates of $414.31 million. During the same period in the previous year, the firm earned $0.41 earnings per share. Integra LifeSciences’s quarterly revenue was up 5.6% compared to the same quarter last year. Integra LifeSciences has set its Q4 2025 guidance at 0.790-0.840 EPS and its FY 2025 guidance at 2.190-2.240 EPS. Sell-side analysts predict that Integra LifeSciences Holdings Corporation will post 2.45 earnings per share for the current year.

Insider Transactions at Integra LifeSciences

In other Integra LifeSciences news, Director Jeffrey A. Graves bought 9,000 shares of the company’s stock in a transaction on Wednesday, November 5th. The stock was acquired at an average price of $11.35 per share, for a total transaction of $102,150.00. Following the completion of the transaction, the director directly owned 41,086 shares of the company’s stock, valued at approximately $466,326.10. This represents a 28.05% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 3.54% of the stock is currently owned by insiders.

Analysts Set New Price Targets

IART has been the subject of several research reports. Wall Street Zen raised shares of Integra LifeSciences from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. JPMorgan Chase & Co. boosted their target price on Integra LifeSciences from $12.00 to $13.00 and gave the stock an “underweight” rating in a research report on Friday, October 31st. Citigroup cut their price target on Integra LifeSciences from $12.00 to $11.00 and set a “sell” rating for the company in a report on Friday, October 31st. Truist Financial reaffirmed a “hold” rating and set a $13.00 price objective (down from $15.00) on shares of Integra LifeSciences in a report on Monday, November 3rd. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Integra LifeSciences in a report on Monday, December 1st. Two research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and three have given a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Reduce” and a consensus price target of $15.00.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.